期刊文献+

紫杉醇联合卡铂辅助化疗治疗三阴性乳腺癌患者临床研究 被引量:2

下载PDF
导出
摘要 目的探究紫杉醇联合卡铂辅助化疗治疗三阴性乳腺癌(TNBC)患者的临床效果。方法选取2012年5月~2017年11月我院48例TNBC患者,依据随机数字表法分为对照组和试验组各24例。对照组予环磷酰胺、表柔比星治疗,试验组予以紫杉醇联合卡铂治疗。观察对比两组治疗总有效率及化疗期间不良反应情况。结果两组治疗总有效率相比,无明显差异(P>0.05),但试验组完全缓解率41.67%较对照组12.50%高(P<0.05);试验组消化系统毒性(肝功能损害、恶心、呕吐、便秘、腹泻)、血液学毒性(中性粒细胞减少、血小板减少)发生率与对照组相比,无明显差异(P>0.05)。结论对TNBC患者予以紫杉醇、卡铂联合治疗,可有效提高完全缓解率,可在保障安全性基础上,增强化疗效果,在临床治疗中值得推广与应用。
作者 杨盼
出处 《现代诊断与治疗》 CAS 2019年第8期1227-1228,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献9

二级参考文献55

  • 1Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J]. N Engl J Med,2010,363(20) :1938-1948.
  • 2Carey LA,Dees EC,Sawyer L, et al. The triple negative para-dox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res,2007,13(8) :2329-2334.
  • 3Iwata H, Sato N, Masuda N, et al. Docetaxel followed by flu-orouracil/epirubicin/cyclophosphamide as neoadjuvant chemo-therapy for patients with primary breast cancer[J]. Jpn J ClinOncol,2011,41(7) :867-875.
  • 4Warm M, Kates R, Grobe-Onnebrink E, et al. Impact of tumorbiology,particularly triple-negative status,on response to preop-erative sequential, dose-dense epirubicin, cyclophosphamide fol-lowed by docetaxel in breast cancer[J]. Anti cancer Res, 2010,30(10):4251-4259.
  • 5Torrisi R.Balduzzi A’Ghisini R, et al. Tailored preoperative treat-ment of locally advanced triple negative (hormone receptor negativeand Her-2 negative) breast cancer with epirubicin, cisplatin.and infu-sional fluorouracil followed by weekly paclitaxel [J]. Cancer Che-mother Pharmacol,2008,62(4) :667-672.
  • 6Eisenhauer EA, Therasse P, Bogaerts J, et al. New response e-valuation criteria in solid tumours: revised RECIST guideline(version 1. 1) [J]. Eur J Cancer,2009,45(2) :228-247.
  • 7Huober J,von Minckwitz G,Denkert C et al. Effect of neoadju-vant anthracycline taxane-based chemotherapy in different bio-logical breast cancer phenotypes : overall results from the Gepar-Trio study[J]. Breast Cancer Res Treat,2010,124(1) : 133-140.
  • 8Wu J, Li S’Jia W, et al. Response and prognosis of taxanes andanthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(10)=1505-1510.
  • 9Liedtke C,Mazouni C,Hess KR,et al. Response to neoadjuvanttherapy and long-term survival in patients with triple-negativebreast cancer[J]. J Clin Oncol,2008’26(8) : 1275-1281.
  • 10Von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatmentcharacteristics on response of different breast cancer phenotypes :pooled analysis of the German neo-adjuvant chemotherapy trials[J].Breast Cancer Res Treat ,2011,125(1) :145-156.

共引文献108

同被引文献19

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部